{"id":2013,"date":"2021-02-22T07:48:40","date_gmt":"2021-02-22T07:48:40","guid":{"rendered":"http:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/?p=2013"},"modified":"2022-04-13T13:59:09","modified_gmt":"2022-04-13T13:59:09","slug":"world-encephalitis-day-enceph-ig-trial","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/world-encephalitis-day-enceph-ig-trial\/","title":{"rendered":"World Encephalitis Day: Enceph-IG Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>World Encephalitis Day on\u00a0<strong>February 22<\/strong>\u00a0is a global awareness day where individuals and families affected by encephalitis (inflammation of the brain) come together to shine a light on the condition. The Centre for Trials Research at Cardiff University is fully co-ordinating the Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults-A Randomised Double-Blind Placebo-Controlled Trial (<a href=\"https:\/\/www.cardiff.ac.uk\/centre-for-trials-research\/research\/studies-and-trials\/view\/enceph-ig\" target=\"_blank\" rel=\"noreferrer noopener\">Enceph-IG Trial<\/a>)<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Autoimmune encephalitis is swelling in the brain caused by the immune system attacking in error. It can cause people to become confused, drowsy, act out of character, and have seizures. It is a rare condition effecting approximately 6,000 people a year in the UK, according to the Encephalitis Society, and even though there are a range of treatment options available to tackle both the causes and symptoms of encephalitis, there isn\u2019t a specific targeted treatment. The Enceph-IG Trial is hoping to help change that.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Typically, patients receive steroids but some patients are given intravenous immunoglobulin (IVIG) because some clinicians think it may help speed up recovery. There have been very few clinical trials looking at recovery time and IVIG use in those with autoimmune encephalitis, so we don\u2019t really know if it is effective at speeding up recovery. IVIG can be associated with significant side effects and is very expensive because it is developed from donated blood. The aim of the current trial is to evaluate how effective early treatment with IVIG is in speeding up recovery from autoimmune encephalitis.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are looking to recruit 356 patients, from 50 hospitals across the UK. The trial will be double blind, this means neither the patients, their families, nor the clinicians treating them will know whether they received IVIG or not. This is to avoid accidentally biasing the results. Once patients are recruited and randomised they will receive steroids and IVIG, or steroids and a placebo (a product that looks identical but which does not contain the active ingredient) for 5 days. Patients will be asked to regularly report on their recovery, and they will be assessed by a clinician at 2 weeks, 3 months, and 12 months after they enter the trial.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are still very early on in the trial set up phase but the impact of COVID on research has meant that we have had to rethink a lot of our standard procedures. A trial comprises of lots of documents, such as detailed protocols and patient information sheets, which are developed collaboratively with the multi-disciplinary team. It has been a challenge to work on all of these documents remotely. Many of the grant collaborators are clinicians and during COVID they have been very busy with their clinical work or were drafted to cover COVID related healthcare. It has been so important before each meeting to identify the key priorities so that we can maximise the time we have with the collaborators and keep the trial moving forward. Given the delays experienced, we have been able to progress and were able to submit our trial for ethical review recently. We will also be utilising more digital tools for data collection and for training site staff in trial activities in order to streamline processes for our clinical teams at sites. We are hoping to start opening our first group of NHS sites in the summer.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Trials in rare disease areas can be difficult to do, so it is very important that any trial actually meets the needs of the specific patient group. The Enceph-IG trial has strong links with the Encephalitis Society, the leading charity advocating for Encephalitis patients and their families in the UK, and their patient advocate group has provided input from the inception of the trial. During the grant development stage, patients and their families were consulted on what they thought the most meaningful outcome would be patients, data collection methods, and frequency of follow up visits. Currently, we have a patient and public representative from Encephalitis Society sitting on our trial management group, and others sitting on our trial steering group.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are very early on in the life cycle of this trial, so we won\u2019t see results for another 5 years but because this is a rare disease area we are hoping that this will be a landmark trial and improve patient treatment for those with encephalitis.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acknowledgements:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trial is funded through the NIHR NIHR Efficacy and Mechanism Evaluation programme (NIHR17\/60\/67).&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Chief Investigator is Professor Tom Solomon, Chair of Neurology University of Liverpool, @RunningMadProf<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Trial Collaborators: Dr Benedict Michael (University of Liverpool), Dr Simon Keller (University of Liverpool), Dr Michael Griffiths (University of Liverpool), Dr Perry Moore (Salford Royal NHS Foundation Trust), Prof Richard Pleass (Liverpool School of Hygiene and Tropical Medicine), Dr Ava Easton (Encephalitis Society), Associate Prof Sarosh Irani (University of Oxford), Dr David Gillespie (Centre for Trials Research), Dr Emma Thomas-Jones (Centre for Trials Research), Dr Sylviane Defres (The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool), Dr Mark Ellul (University of Liverpool), Dr Michael Lunn (University College London Hospital NHS Foundation Trust), Dr Michael Zandi (University College London Hospital NHS Foundation Trust)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trial is sponsored by the University of Liverpool and fully coordinated by the Centre for Trials Research, Cardiff University.<\/p>\n","protected":false},"excerpt":{"rendered":"World Encephalitis Day on\u00a0February 22\u00a0is a global awareness day where individuals and families affected by encephalitis (inflammation of the brain) come together to shine a light on the condition. The [&hellip;]","protected":false},"author":549,"featured_media":2015,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-2013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-wt","jetpack-related-posts":[{"id":2594,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/enceph-ig-trial-the-challenges-of-running-a-rare-disease-trial\/","url_meta":{"origin":2013,"position":0},"title":"ENCEPH-IG Trial: The Challenges Of Running A Rare Disease Trial","author":"Paula Foscarini-Craggs","date":"June 19, 2023","format":false,"excerpt":"Autoimmune encephalitis is swelling of the brain caused by the immune system attacking the body in error. It can cause people to become confused, drowsy, exhibit changes in behaviour, and have seizures. It affects around 1 in 100,000 people per year in the UK and because of its rarity and\u2026","rel":"","context":"In &quot;inflammation and immunity&quot;","block_context":{"text":"inflammation and immunity","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/inflammation-and-immunity\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/06\/ENCEPH-IG.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":2199,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/the-nihr-associate-principal-investigator-scheme-researchers-of-the-future\/","url_meta":{"origin":2013,"position":1},"title":"The NIHR Associate Principal Investigator Scheme: Researchers of the Future","author":"Joanne Euden","date":"March 18, 2022","format":false,"excerpt":"Many of you may have heard of the Associate Principal Investigator (API) scheme, but not everyone is familiar with what it entails and how we, at the Centre for Trials Research (CTR), have involved our studies in this scheme. As more studies and trials are now registering, this blog introduces\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2656,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/global-immune-thrombocytopenia-itp-awareness-week-2023\/","url_meta":{"origin":2013,"position":2},"title":"Global Immune Thrombocytopenia (ITP) Awareness Week 2023","author":"Joanna Smith","date":"September 21, 2023","format":false,"excerpt":"September 25-29th 2023 is Global ITP Awareness Week! This specially designated week calls for individuals around the world to join together to promote public awareness of a rare autoimmune disease called immune thrombocytopenia (ITP). The theme for this year\u2019s Global ITP Awareness Week is Increasing Awareness to Improve Outcomes and\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1902,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/rheumatoid-arthritis-awareness-week-our-research\/","url_meta":{"origin":2013,"position":3},"title":"Rheumatoid Arthritis Awareness Week: Our Research","author":"Timothy Pickles","date":"September 3, 2020","format":false,"excerpt":"Rheumatoid Arthritis Awareness Week Rheumatoid Arthritis Awareness Week takes place on 7-11 September 2020 and is organised by the National Rheumatoid Arthritis Society (NRAS). The Centre for Trials Research is active in a number of studies to help inform evidence base in this important area. There is a focus on\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/09\/SOCRATES-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/09\/SOCRATES-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/09\/SOCRATES-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/09\/SOCRATES-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":2030,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/purple-day-2021-why-epilepsy-research-is-so-vital\/","url_meta":{"origin":2013,"position":4},"title":"Purple Day 2021: Why Epilepsy Research Is So Vital","author":"Cheney Drew","date":"March 26, 2021","format":false,"excerpt":"The 26th\u00a0March is otherwise known as \u2018Purple Day\u2019- a day where people are encouraged to where purple in recognition and support of people with epilepsy (PwE). Epilepsy is the most common chronic neurological condition, affecting between 1-3% of the population. It can affect anyone and although specific epilepsy syndromes ae\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/03\/Epilepsy.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/03\/Epilepsy.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/03\/Epilepsy.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/03\/Epilepsy.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":2558,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/trial-governance-placement-scheme-launch\/","url_meta":{"origin":2013,"position":5},"title":"Trial Governance Placement Scheme Launch","author":"Rachel McNamara","date":"April 11, 2023","format":false,"excerpt":"The Centre for Trials Research (CTR) based at Cardiff University is delighted to be working in partnership with the Health Research Board-Trials Methodology Research Network (HRB-TMRN) in Ireland, to launch the new Trial Governance Placement Scheme from March 2023. This is a fantastic opportunity for the CTR to forge a\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/04\/TGPS.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/549"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=2013"}],"version-history":[{"count":2,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2013\/revisions"}],"predecessor-version":[{"id":2016,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2013\/revisions\/2016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media\/2015"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=2013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=2013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=2013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}